Teleflex (TFX) Q2 2024 earnings summary

Executive summary

• Q2 2024 GAAP revenue rose 0.9% year-over-year to $749.7 million; adjusted revenue up 2.7% to $763.5 million, or 3.4% on a constant currency basis, driven by price increases and new product sales, partially offset by the Italian payback reserve.

• Adjusted EPS for the quarter was $3.42, a 0.3% increase year-over-year, while GAAP diluted EPS was $1.69, down from $2.35, reflecting higher SG&A and a $138.1 million pension settlement charge.

• The company increased 2024 revenue and adjusted EPS guidance, supported by robust first-half results, expected intra-aortic balloon pump sales in Q4, and strong Interventional and EMEA segment performance.

• Announced a $500 million share repurchase program, including a $200 million accelerated share repurchase commencing August 2024.

• Palette Life Sciences (Barrigel) acquisition integration is ongoing and performing ahead of expectations.

Financial highlights

• Q2 2024 gross margin improved to 55.6% (GAAP) and 60.8% (adjusted), up 180 basis points year-over-year, aided by cost initiatives and MSA termination.

• Adjusted operating margin reached 26.7% (up 10 bps YoY); GAAP operating margin was 15.6% (down from 19.3%).

• Cash flow from operations for the first six months was $204.5 million, up from $170.6 million in the prior year.

• Net leverage at quarter end was approximately 1.6x, rising to 1.9x pro forma for the $200 million ASR.

• Interest expense rose to $21.2 million in Q2 2024, reflecting higher rates and increased average debt.

Outlook and guidance

• 2024 adjusted constant currency revenue growth guidance raised to 4.25%-5.25%; GAAP revenue growth guidance raised to 3.40%-4.40%.

• 2024 adjusted EPS guidance increased to $13.80-$14.20, representing 2.1%-5.0% growth; GAAP EPS guidance lowered to $6.43-$6.83.

• Gross margin guidance raised to 60.25%-61%; operating margin guidance raised to 26.5%-27%.

• Third quarter revenue expected at $765-$770 million, up 3.1%-3.7% year-over-year.

• Incremental intra-aortic balloon pump revenue expected in Q4 2024, with continued opportunity into at least the first half of 2025.